Novartis CEO Vas Narasimhan (via AP Images)

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle biotech

No­var­tis this morn­ing re­port­ed that their asth­ma drug fe­vip­iprant flunked two more Phase III stud­ies, crush­ing their hopes in what had been a star …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.